People with bipolar disorder (BD) and major depressive disorder (MDD) are at risk for premature death from various physical illnesses. A large component of this risk may be accounted for by an elevated risk of metabolic syndrome (MeS) and coronary heart disease (CHD). The objective of our study was to examine patients' physical health prior to first treatment and over 2 years of follow-up.
Methods:
Ten-year risk for CHD and incidence of MeS were calculated for newly diagnosed patients with MDD (n = 30) and BD (n = 24) at baseline and over a 2-year follow-up. Age and sex-matched control subjects were obtained from the National Health and Nutrition Examination Survey III dataset.
Results:
At baseline, 11.2% of patients met diagnostic criteria for MeS and this increased to 16.8% at follow-up. Women had higher rates of MeS but rates were similar across diagnosis. There was a significant increase within all MeS criteria. The 10-year CHD risk was low for patients at baseline and follow-up but increased across the follow-up period. Changes in CHD and MeS risk were not associated with a specific type of pharmacotherapy, as all medication classes appeared to increase risk.
Conclusion:
Prior to treatment, MeS and CHD risk rates for patients were similar to the general population, but their risk of CHD increased appreciably.
EckelRHGrundySMZimmetPZ. The metabolic syndrome. Lancet. 2005;365:1415–1428.
2.
GrundySMCleemanJIDanielsSR. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752.
3.
LaaksonenDELakkaHMNiskanenLK. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–1077.
4.
IsomaaBHenricssonMAlmgrenP. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia. 2001;44:1148–1154.
5.
LakkaHMLaaksonenDELakkaTA. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716.
6.
AlbertiGZimmetPShawJ.A new IDF worldwide definition of the metabolic syndrome: The rationale and the results. Diabetes Voice. 2005;50.
7.
NewcomerJ. W.Metabolic syndrome and mental illness. Am J Manag Care. 2007;13:S170–S177.
8.
McIntyreRSKonarskiJZWilkinsK. Obesity in bipolar disorder and major depressive disorder: Results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51:274–280.
9.
McEvoyJPMeyerJMGoffDC. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19–32.
10.
YathamLNKennedySHO'DonovanC. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Update 2007. Bipolar Disord. 2006;8:721–739.
11.
ParikhSVLamRW. Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden. Can J Psychiatry. 2001;46(5 Suppl 1):13S–20S.
12.
KannelWBMcGeeDL. Diabetes and cardiovascular risk factors: The Framingham study. Circulation. 1979;59:8–13.
13.
FeinleibMKannelWBGarrisonRJ. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975;4:518–525.
14.
WilsonPWD'AgostinoRBLevyD. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847.
15.
FirstMBSpitzerRLGibbonM. Structured Clinical Interview for DSM-IV. New York (NY): Biometrics Research Department, New York State Psychiatry Institute; 1994.
16.
HamiltonM.A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
17.
YoungRCBiggsJTZieglerVE. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.
18.
YumruMSavasHAKurtE. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2007;98:247–252.
19.
StunkardAJFaithMSAllisonKC. Depression and obesity. Biol Psychiatry. 2003;54:330–337.
20.
KinderLSCarnethonMRPalaniappanLP. Depresson and the metabolic syndrome in young adults: Findings from the Third National Health and Nutrition Examination Survey. Psychosom Med. 2004;66:316–322.
21.
ThakoreJHRichardsPJReznekRH. Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol Psychiatry. 1997;41:1140–1142.
22.
Everson-RoseSAMeyerPMPowellLH. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care. 2004;27:2856–2862.
23.
Regitz-ZagrosekVLehmkuhlEWeickertMO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006;95:136–147.
24.
FordESGilesWHMokdadAH. Increasing prevalence of the metabolic syndrome among US Adults. Diabetes Care. 2004;27:2444–2449.
25.
SteinbaumSR. The metabolic syndrome: An emerging health epidemic in women. Prog Cardiovasc Dis. 2004;46:321–336.
26.
OlfsonMMarcusSCPincusHA. Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry. 1998;55:310–316.
27.
HermannRCYangDEttnerSL. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989–1997. Psychiatr Serv. 2002;53:425–430.
28.
TaylorVHMacdonaldKMcKinnonMC. Increased rates of obesity in first presentation adults with mood disorders over the course of four year follow-up. J Affect Disord. 2008;109:127–131.
29.
RosamondWDChamblessLEFolsomAR. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease. N Engl J Med. 1998;339:861–867.
30.
LeviFLucchiniFNegriE. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart. 2002;88:119–124.
31.
KesslerRCMcGonagleKAZhaoS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.
32.
ColtonCWManderscheidRW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3:A42.
33.
ComptonMTDaumitGLDrussBG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: A preventive perspective. Harv Rev Psychiatry. 2006;14:212–222.
34.
DrussBGRohrbaughRMLevinsonCM. Integrated medical care for patients with serious psychiatric illness: A randomized trial. Arch Gen Psychiatry. 2001;58:861–868.
HeiskanenTHNiskanenLKHintikkaJJ. Metabolic syndrome and depression: A cross-sectional analysis. J Clin Psychiatry. 2006;67:1422–1427.
37.
SimonGEVon KorffMSaundersK. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63:824–830.
38.
ZimmermanUKrausTHimmerichH. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res. 2003;37:193–220.
39.
CorrellCUFredericksonAMKaneJM. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006;67:575–583.
40.
AndersohnFSchadeRSuissaS. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591–598.
